Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis DOI Open Access
Martina Maurelli, Paolo Gisondi, Francesco Bellinato

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(18), P. 6057 - 6057

Published: Sept. 19, 2023

There are no published studies on the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with atopic dermatitis (AD). To estimate NAFLD (assessed via ultrasonography) adults moderate-to-severe AD. We performed a retrospective, cross-sectional, observational study including adult affected by AD, chronic plaque psoriasis, or previous diagnosis thin melanoma situ (considered as control group) who attended Verona University Hospital between January 2022 and April 2023. Fatty was assessed ultrasonography. A total 144 466 99 were included. The rates ultrasound-detected among melanoma, those psoriasis 23.2% (23 out 99), 24.1% (36 144), 49.8% (228 466), respectively (p < 0.01). Logistic regression analysis revealed that being male sex, higher age, body mass index, independently associated NAFLD, whereas AD not. Our findings show comparable to melanoma. It is plausible hypothesize Th2-type inflammation typically characterizing not risk factor for NAFLD. Patients but should be screened other metabolic comorbidities.

Language: Английский

Urinary α1 microglobulin level is useful for selecting sodium‐glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes DOI
Masaya Koshizaka, Ryoichi Ishibashi, Ko Ishikawa

et al.

Diabetes Obesity and Metabolism, Journal Year: 2023, Volume and Issue: 25(10), P. 3071 - 3075

Published: June 29, 2023

Chiba University and Astellas Pharma Inc. signed a contract to conduct the study. The funding source did not play any role in study design, execution, data analysis interpretation, manuscript preparation, or decision publish. KY received lecture fees from Inc., MSD Sumitomo Co. Ltd. other authors have no conflicts of interest declare. peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15188. datasets generated during and/or analyzed current are corresponding author on reasonable request. Table S1. Baseline clinical characteristics patients each drug group. S2. Multivariate logistic regression visceral fat area reduction responders ipragliflozin S3. metformin Please note: publisher responsible content functionality supporting information supplied by authors. Any queries (other than missing content) should be directed article.

Language: Английский

Citations

1
Effects of SGLT2i and Pioglitazone on FIB-4 Index in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease—A Real World Retrospective Study from India DOI Creative Commons
Krishna Seshadri,

Dakshata Padhye,

Surekha Tippisetty

et al.

International journal of clinical metabolism and diabetes., Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 21, 2024

Aims: Several studies support type 2 diabetes mellitus (T2DM) as one of the risk factors metabolic dysfunction associated steatotic liver disease (MASLD). Recently, use pioglitazone and sodium-glucose co-transporter inhibitors (SGLT2i) has been on rise considering its beneficial effects in reducing dysfunction. We aim to determine clinical effectiveness these drugs improving MASLD T2DM. Materials methods: conducted a retrospective study 279 T2DM patients with who were prescribed and/or SGLT2i from two clinics India. The primary endpoint was change fibrosis (FIB-4) index aspartate aminotransferase platelet ratio (APRI) score at year follow-up. Appropriate statistical tests applied assess significance outcomes. Results: Of total (276) patients, 46% low advanced fibrosis, 11% high for majority (50%) treatment. At follow-up, there is statistically significant reduction mean (SD) FIB-4 (1.92 [1.22] vs. 1.68 [0.99]) APRI (0.42 [0.34] 0.33 [0.21]); p < .001. Among treatment groups, difference both baseline (F: 4.23; .05) follow-up 3.45; .05). These scores highly combination ( Conclusions: Our results indicate therapy might be managing MASLD, especially Indian MASLD.

Language: Английский

Citations

0
Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis DOI Open Access
Martina Maurelli, Paolo Gisondi, Francesco Bellinato

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(18), P. 6057 - 6057

Published: Sept. 19, 2023

There are no published studies on the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with atopic dermatitis (AD). To estimate NAFLD (assessed via ultrasonography) adults moderate-to-severe AD. We performed a retrospective, cross-sectional, observational study including adult affected by AD, chronic plaque psoriasis, or previous diagnosis thin melanoma situ (considered as control group) who attended Verona University Hospital between January 2022 and April 2023. Fatty was assessed ultrasonography. A total 144 466 99 were included. The rates ultrasound-detected among melanoma, those psoriasis 23.2% (23 out 99), 24.1% (36 144), 49.8% (228 466), respectively (p < 0.01). Logistic regression analysis revealed that being male sex, higher age, body mass index, independently associated NAFLD, whereas AD not. Our findings show comparable to melanoma. It is plausible hypothesize Th2-type inflammation typically characterizing not risk factor for NAFLD. Patients but should be screened other metabolic comorbidities.

Language: Английский

Citations

0